R&D CAMP4 on a new class of ASO in gene under expression CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
News CAMP4 raises $100m to take lead RNA drugs into clinic Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to
Digital Sponsored Antiviral development in the age of AI: From pre-IND to earl... hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
